This company has been acquired
Applied Genetic Technologies Past Earnings Performance
Past criteria checks 0/6
Key information
-39.8%
Earnings growth rate
-21.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -57.4% |
| Return on equity | -398.0% |
| Net Margin | -21,610.5% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
AGTC receives positive feedback from FDA for manufacturing facility
Jul 26Applied Genetic Technologies proposes stock offering to fund clinical trials
Jul 12Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022
Jan 12An Assessment Of Applied Genetic Technologies Corporation
Dec 14Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk
Jul 15Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?
May 21
What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?
Feb 05
Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?
Jan 06What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Dec 11Revenue & Expenses Breakdown
How Applied Genetic Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -70 | 17 | 28 |
| 30 Jun 22 | 0 | -69 | 17 | 28 |
| 31 Mar 22 | 1 | -63 | 17 | 25 |
| 31 Dec 21 | 1 | -63 | 16 | 23 |
| 30 Sep 21 | 1 | -60 | 15 | 22 |
| 30 Jun 21 | 1 | -58 | 15 | 21 |
| 31 Mar 21 | 0 | -60 | 14 | 21 |
| 31 Dec 20 | 0 | -57 | 14 | 21 |
| 30 Sep 20 | 2 | -50 | 14 | 27 |
| 30 Jun 20 | 2 | -46 | 14 | 21 |
| 31 Mar 20 | 3 | -42 | 13 | 21 |
| 31 Dec 19 | 24 | -19 | 13 | 29 |
| 30 Sep 19 | 28 | -15 | 13 | 20 |
| 30 Jun 19 | 42 | -2 | 13 | 19 |
| 31 Mar 19 | 47 | 2 | 13 | 2 |
| 31 Dec 18 | 29 | -18 | 14 | 1 |
| 30 Sep 18 | 28 | -19 | 14 | 5 |
| 30 Jun 18 | 24 | -21 | 14 | 0 |
| 31 Mar 18 | 27 | -18 | 14 | 27 |
| 31 Dec 17 | 32 | -11 | 13 | 15 |
| 30 Sep 17 | 38 | -4 | 12 | 15 |
| 30 Jun 17 | 39 | 0 | 11 | 15 |
| 31 Mar 17 | 43 | 6 | 11 | 11 |
| 31 Dec 16 | 47 | 10 | 10 | 11 |
| 30 Sep 16 | 48 | 11 | 10 | 11 |
| 30 Jun 16 | 47 | -1 | 10 | 11 |
| 31 Mar 16 | 36 | -12 | 10 | 0 |
| 31 Dec 15 | 24 | -20 | 11 | 0 |
Quality Earnings: AGTC is currently unprofitable.
Growing Profit Margin: AGTC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AGTC is unprofitable, and losses have increased over the past 5 years at a rate of 39.8% per year.
Accelerating Growth: Unable to compare AGTC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AGTC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (60.8%).
Return on Equity
High ROE: AGTC has a negative Return on Equity (-398.02%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/12/01 16:07 |
| End of Day Share Price | 2022/11/30 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2022/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Applied Genetic Technologies Corporation is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Birchenough | BMO Capital Markets Equity Research |
| Yun Zhong | BTIG |
| Kristen Kluska | Cantor Fitzgerald & Co. |